TY - JOUR T1 - Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01898-2017 SP - 1701898 AU - O Brugière AU - A Roux AU - J Le Pavec AU - D Sroussi AU - F Parquin AU - P Pradère AU - C Dupin AU - V Bunel AU - G Mourin AU - G Jebrak AU - G Dauriat AU - Y Castier AU - P Mordant AU - B Lortat-Jacob AU - S Jean-Baptiste AU - H Mal AU - C Suberbielle AU - C Gautreau AU - S Caillat-Zucman AU - A Cazes AU - G Thabut AU - JL Taupin Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/06/14/13993003.01898-2017.abstract N2 - Rationale: Presence of anti-HLA donor-specific antibodies (DSAs) is associated with poor outcome after lung transplantation (LTx). DSAs are currently detected by Luminex technique, which may be overly sensitive. The new C1q assay allows for the exclusive detection of complement (C1q)-binding antibodies, involved in antibody-mediated rejection.Objectives: To investigate whether early detection of complement-binding DSAs is associated with chronic lung allograft dysfunction (CLAD) and survival.Methods: From 2009–2012, LTx recipients from 3 transplantation centers were screened for the presence of DSA and their complement-binding capacity during the 6–12 months post-transplantation in stable condition.Results: The analysis included 168 patients. The 3-year rates of freedom from CLAD and graft survival were lower for patients with complement-binding DSAs (33.6% and 53.7%, respectively), as compared with patients with non–complement-binding DSAs (61.9% and 77.4%, respectively) and patients without DSA (70% and 84.9%, respectively) (p<0.001 and p=0.001,respectively). Detection of complement-binding DSA was associated with a risk of graft loss that was nearly tripled after adjustement for clinical, functional, histologic, and immunologic factors (hazard ratio, 2.98; 95% CI,1.33 to 6.66;p=0.008).Conclusion: Assessment of the C1q-binding capacity of DSA appears to be useful in identifying stable lung transplant recipients at high risk for lung-allograft loss.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Brugière has nothing to disclose.Conflict of interest: Dr. Roux has nothing to disclose.Conflict of interest: Dr. Sroussi has nothing to disclose.Conflict of interest: Dr. PARQUIN has nothing to disclose.Conflict of interest: Dr. Pradere has nothing to disclose.Conflict of interest: Dr. Dupin has nothing to disclose.Conflict of interest: Dr. Bunel has nothing to disclose.Conflict of interest: G. MourinConflict of interest: Dr. Jebrak has nothing to disclose.Conflict of interest: Dr. Dauriat has nothing to disclose.Conflict of interest: Dr. Castier has nothing to disclose.Conflict of interest: Dr. Mordant has nothing to disclose.Conflict of interest: Dr. LORTAT-JACOB has nothing to disclose.Conflict of interest: Dr. Jean-Baptiste has nothing to disclose.Conflict of interest: Dr. Mal reports personal fees from Roche, personal fees from Boehringer, personal fees from csl behring, outside the submitted work; .Conflict of interest: Dr. Suberbielle has nothing to disclose.Conflict of interest: Dr. GAUTREAU has nothing to disclose.Conflict of interest: Dr. Caillat-Zucman has nothing to disclose.Conflict of interest: Dr. Cazes has nothing to disclose.Conflict of interest: Dr. Thabut has nothing to disclose.Conflict of interest: Dr. TAUPIN has nothing to disclose.Conflict of interest: Dr. Le Pavec has nothing to disclose. ER -